sGC stimulators

1. A compound according to Formula I, or a pharmaceutically acceptable salt thereof,

wherein:

ring B is a phenyl or a 6-membered heteroaryl ring, containing 1 or 2 nitrogen atoms in the ring;

n is an integer selected from 0 to 3;

each j B is independently selected from halogen, —CN, —NO 2 , a C 1-6 aliphatic, —OR B or a C 3-8 cycloaliphatic group; wherein each said C 1-6 aliphatic and each said C 3-8 cycloaliphatic group is optionally and independently substituted with up to 3 instances of R 3 ;

each R B is independently selected from hydrogen, a C 1-6 aliphatic or a C 3-8 cycloaliphatic; wherein each said C 1-6 aliphatic and each said C 3-8 cycloaliphatic ring is optionally and independently substituted with up to 3 instances of R 3 ;

each R 3 is independently selected from halogen, —CN, C 1-4 alkyl, C 1-4 haloalkyl, —O(C 1-4 alkyl) or —O(C 1-4 haloalkyl);

X is selected from N, C-J D or C—H;

o is an integer selected from 0 to 3;

each J D is independently selected from halogen, —NO 2 , —OR D , —SR D , —C(O)R D , —C(O)OR D , —C(O)N(R D ) 2 , —CN, —N(R D ) 2 , —N(R d )C(O)R D , —N(R d )C(O)OR D , —SO 2 R D , —SO 2 N(R D ) 2 , —N(R d )SO 2 R D , a C 1-6 aliphatic, —(C 1-6 aliphatic)-R D , a C 3-8 cycloaliphatic ring, a 6 to 10-membered aryl ring, a 4 to 8-membered heterocyclic ring or a 5 to 10-membered heteroaryl ring; wherein each said 4 to 8-membered heterocylic ring and each said 5 to 10-membered heteroaryl ring contains between 1 and 3 heteroatoms independently selected from O, N or S; and wherein each said C 1-6 aliphatic, each said C 3-8 cycloaliphatic ring, each said 6 to 10-membered aryl ring, each said 4 to 8-membered heterocyclic ring and each said 5 to 10-membered heteroaryl ring is optionally and independently substituted with up to 3 instances of R 5 ;

each R D is independently selected from hydrogen, a C 1-6 aliphatic, —(C 1-6 aliphatic)-R f , a C 3-8 cycloaliphatic ring, a 4 to 8-membered heterocyclic ring, phenyl or a 5 to 6-membered heteroaryl ring; wherein each said 4 to 8-membered heterocylic ring and each said 5 to 6-membered heteroaryl ring contains between 1 and 3 heteroatoms independently selected from O, N or S; and wherein each said C 1-6 aliphatic, each said C 3-8 cycloaliphatic ring, each said 4 to 8-membered heterocyclic ring, each said phenyl and each said 5 to 6-membered heteroaryl ring is optionally and independently substituted with up to 3 instances of R 5 ;

each R d is independently selected from hydrogen, a C 1-6 aliphatic, —(C 1-6 aliphatic)-R f , a C 3-8 cycloaliphatic ring, a 4 to 8-membered heterocyclic ring, phenyl or a 5 to 6-membered heteroaryl ring; wherein each said heterocylic ring and each said heteroaryl ring contains between 1 and 3 heteroatoms independently selected from O, N or S; and wherein each said C 1-6 aliphatic, each said C 3-8 cycloaliphatic ring, each said 4 to 8-membered heterocyclic ring, each said phenyl and each said 5 to 6-membered heteroaryl ring is optionally and independently substituted by up to 3 instances of R 5 ;

each R f is independently selected from a C 3-8 cycloaliphatic ring, a 4 to 8-membered heterocyclic ring, phenyl or a 5 to 6-membered heteroaryl ring; wherein each said heterocylic ring and each said heteroaryl ring contains between 1 and 3 heteroatoms independently selected from O, N or S; and wherein each said C 1-6 aliphatic, each said C 3-8 cycloaliphatic ring, each said 4 to 8-membered heterocyclic ring, each said phenyl and each said 5 to 6-membered heteroaryl ring is optionally and independently substituted by up to 3 instances of R 5 ;

alternatively, two instances of R D linked to the same nitrogen atom of J D , together with said nitrogen atom of J D , form a 4 to 8-membered heterocyclic ring or a 5-membered heteroaryl ring; wherein each said 4 to 8-membered heterocyclic ring and each said 5-membered heteroaryl ring optionally contains up to 2 additional heteroatoms independently selected from N, O or S, and wherein each said 4 to 8-membered heterocyclic ring and each said 5-membered heteroaryl ring is optionally and independently substituted by up to 3 instances of R 5 ; or

alternatively, one instance of R D linked to a carbon, oxygen or sulfur atom of J D and one instance of R d linked to a nitrogen atom of the same J D , together with said carbon, oxygen or sulfur and said nitrogen atom of that same J D , form a 4 to 8-membered heterocyclic ring or a 5-membered heteroaryl ring; wherein each said 4 to 8-membered heterocyclic ring and each said 5-membered heteroaryl ring optionally contains up to 2 additional heteroatoms independently selected from N, O or S, and wherein each said 4 to 8-membered heterocyclic ring and each said 5-membered heteroaryl ring is optionally and independently substituted by up to 3 instances of R 5 ;

each R 5 is independently selected from halogen, —CN, —NO 2 , C 1-4 alkyl, a C 7-12 aralkyl, C 3-8 cycloalkyl ring, C 1-4 haloalkyl, C 1-4 cyanoalkyl, —OR 6 , —SR 6 , —COR 6 , —OC(O)R 6 , —C(O)OR 6 , —C(O)N(R 6 ) 2 , —N(R 6 )C(O)R 6 , —N(R 6 ) 2 , —SO 2 R 6 , —SO 2 N(R 6 ) 2 , —N(R 6 )SO 2 R 6 , phenyl or an oxo group; wherein each said phenyl group is optionally and independently substituted with up to 3 instances of halogen, —OH, —NH 2 , —NH(C 1-4 alkyl), —N(C 1-4 alkyl) 2 , —NO 2 , —CN, C 1-4 alkyl, C 1-4 haloalkyl, —O(C 1-4 alkyl) or —O(C 1-4 haloalkyl); and wherein each said C 7-12 aralkyl and each said cycloalkyl group is optionally and independently substituted with up to 3 instances of halogen;

with the proviso that when X is C—H, each R 5 is independently selected from halogen, —CN, —NO 2 , methyl, ethyl, a C 7-12 aralkyl, C 3-8 cycloalkyl ring, C 1-4 haloalkyl, C 1-4 cyanoalkyl, —OR 6 , —SR 6 , —COR 6 , —OC(O)R 6 , —C(O)OR 6 , —C(O)N(R 6 ) 2 , —N(R 6 )C(O)R 6 , —N(R 6 ) 2 , —SO 2 R 6 , —SO 2 N(R 6 ) 2 , —N(R 6 )SO 2 R 6 , phenyl or an oxo group; wherein each said phenyl group is optionally and independently substituted with up to 3 instances of halogen, —OH, —NH 2 , —NH(C 1-4 alkyl), —N(C 1-4 alkyl) 2 , —NO 2 , —CN, C 1-4 alkyl, C 1-4 haloalkyl, —O(C 1-4 alkyl) or —O(C 1-4 haloalkyl); and wherein each said C 7-12 aralkyl and each said cycloalkyl group is optionally and independently substituted with up to 3 instances of halogen;

each R 6 is independently selected from hydrogen, a C 1-4 alkyl, a C 2-4 alkenyl, phenyl, a C 7-12 aralkyl or a C 3-8 cycloalkyl ring; wherein each of said C 1-4 alkyl, each said C 2-4 alkenyl, each said phenyl, each said C 7-12 aralkyl and each said cycloalkyl group is optionally and independently substituted with up to 3 instances of halogen;

alternatively, two instances of R 6 linked to the same nitrogen atom of R 5 , together with said nitrogen atom of R 5 , form a 5 to 8-membered heterocyclic ring or a 5-membered heteroaryl ring; wherein each said 5 to 8-membered heterocyclic ring and each said 5-membered heteroaryl ring optionally contains up to 2 additional heteroatoms independently selected from N, O or S; or

alternatively, one instance of R 6 linked to a nitrogen atom of R 5 and one instance of R 6 linked to a carbon or sulfur atom of the same R 5 , together with said nitrogen and said carbon or sulfur atom of the same R 5 , form a 5 to 8-membered heterocyclic ring or a 5-membered heteroaryl ring; wherein each said 5 to 8-membered heterocyclic ring and each said 5-membered heteroaryl ring optionally contains up to 2 additional heteroatoms independently selected from N, O or S;

or, alternatively, two J D groups attached to two vicinal ring D atoms, taken together with said two vicinal ring D atoms, form a 5 to 7-membered heterocycle resulting in a fused ring D wherein said 5 to 7-membered heterocycle contains from 1 to 3 heteroatoms independently selected from N, O or S; and wherein said 5 to 7-membered heterocycle is optionally and independently substituted by up to 3 instances of halogen, —OH, —NH 2 , —NH(C 1-4 alkyl), —N(C 1-4 alkyl) 2 , —CN, C 1-4 alkyl, C 1-4 haloalkyl, —O(C 1-4 alkyl), —O(C 1-4 haloalkyl) oxo or phenyl; wherein said phenyl is optionally and independently substituted by up to three instances of halogen, —OH, —NH 2 , —NH(C 1-4 alkyl), —N(C 1-4 alkyl) 2 , —NO 2 , —CN, C 1-4 alkyl, C 1-4 haloalkyl, —O(C 1-4 alkyl) or —O(C 1-4 haloalkyl);

R C is selected from —CN, C 1-6 alkyl or a ring C;

ring C is a phenyl ring, a monocyclic 5 or 6-membered heteroaryl ring, a bicyclic 8 to 10-membered heteroaryl ring, a monocyclic 3 to 10-membered cycloaliphatic ring, or a monocyclic 4 to 10-membered heterocycle; wherein said monocyclic 5 or 6-membered heteroaryl ring, said bicyclic 8 to 10-membered heteroaryl ring, or said monocyclic 4 to 10-membered heterocycle contain between 1 and 4 heteroatoms selected from N, O or S; wherein said monocyclic 5 or 6-membered heteroaryl ring is not a 1,3,5-triazinyl ring; and wherein said phenyl, monocyclic 5 to 6-membered heteroaryl ring, bicyclic 8 to 10-membered heteroaryl ring, or monocyclic 4 to 10-membered heterocycle is optionally and independently substituted with up to 3 instances of J C ;

each J C is independently selected from halogen, —CN, —NO 2 , a C 1-6 aliphatic, —OR H , —SR H , —N(R H ) 2 , a C 3-8 cycloaliphatic ring or a 4 to 8-membered heterocyclic ring; wherein said 4 to 8-membered heterocyclic ring contains 1 or 2 heteroatoms independently selected from N, O or S; wherein each said C 1-6 aliphatic, each said C 3-8 cycloaliphatic ring and each said 4 to 8-membered heterocyclic ring, is optionally and independently substituted with up to 3 instances of R 7 ; or alternatively, two J C groups attached to two vicinal ring C atoms, taken together with said two vicinal ring C atoms, form a 5 to 7-membered heterocycle resulting in a fused ring C; wherein said 5 to 7-membered heterocycle contains from 1 to 2 heteroatoms independently selected from N, O or S;

each R H is independently selected from hydrogen, a C 1-6 aliphatic, a C 3-8 cycloaliphatic ring or a 4 to 8-membered heterocyclic ring; wherein each said 4 to 8-membered heterocylic ring contains between 1 and 3 heteroatoms independently selected from O, N or S; and wherein each said C 1-6 aliphatic, each said C 3-8 cycloaliphatic ring, each said 4 to 8-membered heterocyclic ring, is optionally and independently substituted with up to 3 instances of R 7 ;

alternatively, two instances of R H linked to the same nitrogen atom of J C , together with said nitrogen atom of J C , form a 4 to 8-membered heterocyclic ring or a 5-membered heteroaryl ring; wherein each said 4 to 8-membered heterocyclic ring and each said 5-membered heteroaryl ring optionally contains up to 2 additional heteroatoms independently selected from N, O or S, and wherein each said 4 to 8-membered heterocyclic ring and each said 5-membered heteroaryl ring is optionally and independently substituted by up to 3 instances of R 7 ; or

each R 7 is independently selected from halogen, —CN, —NO 2 , C 1-4 alkyl, C 1-4 haloalkyl, C 3-8 cycloalkyl ring, —OR 8 , —SR 8 , —N(R 8 ) 2 , or an oxo group; wherein each said cycloalkyl group is optionally and independently substituted with up to 3 instances of halogen;

each R 8 is independently selected from hydrogen, a C 1-4 alkyl, C 1-4 haloalkyl or a C 3-8 cycloalkyl ring; wherein each said cycloalkyl group is optionally and independently substituted with up to 3 instances of halogen;

alternatively, two instances of R 8 linked to the same nitrogen atom of R 7 , together with said nitrogen atom of R 7 , form a 5 to 8-membered heterocyclic ring or a 5-membered heteroaryl ring; wherein each said 5 to 8-membered heterocyclic ring and each said 5-membered heteroaryl ring optionally contains up to 2 additional heteroatoms independently selected from N, O or S;

R A is selected from hydrogen, halogen, C 1-4 alkyl or C 1-4 haloalkyl,

with the proviso that when ring B is unsubstituted phenyl and ring D is unsubstituted pyrimidinyl (X is N and o is zero), R C is not methyl or ethyl.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein ring B is phenyl.

3. The compound of claim 1 or claim 2 , or a pharmaceutically acceptable salt thereof, wherein n is an integer selected from 1 to 3 and wherein each J B is independently selected from halogen, a C 1-6 aliphatic or —OR B .

4. The compound of claim 3 , or a pharmaceutically acceptable salt thereof, wherein each J B is independently selected from halogen atoms.

5. The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein each J B is independently selected from fluoro or chloro.

6. The compound of claim 5 , or a pharmaceutically acceptable salt thereof, wherein each J B is fluoro.

7. The compound of claim 3 , or a pharmaceutically acceptable salt thereof, wherein each J B is a C 1-6 aliphatic.

8. The compound of claim 7 , or a pharmaceutically acceptable salt thereof, wherein each J B is methyl or ethyl.

9. The compound of claim 3 , or a pharmaceutically acceptable salt thereof, wherein n is 1.

10. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein J B is selected from halogen atoms.

11. The compound of claim 10 , or a pharmaceutically acceptable salt thereof, wherein J B is fluoro or chloro.

12. The compound of claim 11 , or a pharmaceutically acceptable salt thereof, wherein J B is fluoro.

13. The compound of claim 3 , or a pharmaceutically acceptable salt thereof, wherein at least one J B is ortho to the attachment of the methylene linker between ring B and the pyrazolyl ring.

14. The compound of claim 13 , or a pharmaceutically acceptable salt thereof, wherein each J B is independently selected from halogen atoms.

15. The compound of claim 14 , or a pharmaceutically acceptable salt thereof, wherein each J B is independently selected from fluoro or chloro.

16. The compound of claim 15 , or a pharmaceutically acceptable salt thereof, wherein each J B is fluoro.

17. The compound of claim 13 , or a pharmaceutically acceptable salt thereof, wherein n is 1 and the J B ortho to the attachment of the methylene linker between ring B and the pyrazolyl ring is fluoro.

18. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein ring B is a 6-membered heteroaryl ring.

19. The compound of claim 18 , or a pharmaceutically acceptable salt thereof, wherein ring B is a pyridyl ring.

20. The compound of claim 18 , or a pharmaceutically acceptable salt thereof, wherein ring B is a pyrimidinyl ring.

21. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X in ring D is C-J D or C—H.

22. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X in ring D is N.

23. The compound of either of claims 21 or 22 , or a pharmaceutically acceptable salt thereof, wherein o is 0.

24. The compound of either of claims 21 or 22 , or a pharmaceutically acceptable salt thereof, wherein o is an integer selected between 1 and 3 and each J D is independently selected from halogen, a C 1-6 aliphatic, —N(R D ) 2 , —N(R d )C(O)R D , —N(R d )C(O)OR D , —SO 2 R D , —SO 2 N(R D ) 2 , —N(R d )SO 2 R D , —SR D , —OR D or an optionally substituted C 3-8 cycloaliphatic ring.

25. The compound of claim 24 , or a pharmaceutically acceptable salt thereof, wherein each J D is independently selected from halogen atoms.

26. The compound of claim 25 , or a pharmaceutically acceptable salt thereof, wherein each J D is independently selected from a chloro or fluoro.

27. The compound of claim 24 , or a pharmaceutically acceptable salt thereof, wherein each J D is independently selected from a C 1-6 aliphatic or a C 3-8 cycloaliphatic ring.

28. The compound of claim 27 , or a pharmaceutically acceptable salt thereof, wherein each J D is independently methyl or ethyl, propyl, cyclobutyl, cyclopropyl or isopropyl.

29. The compound of claim 28 , or a pharmaceutically acceptable salt thereof, wherein each J D is independently methyl, ethyl or cyclopropyl.

30. The compound of claim 24 , or a pharmaceutically acceptable salt thereof, wherein each J D is independently selected from —N(R D ) 2 , —N(R d )C(O)R D , —N(R d )C(O)OR D , —SO 2 R D , —SO 2 N(R D ) 2 , —N(R d )SO 2 R D or —OR D .

31. The compound of claim 30 , or a pharmaceutically acceptable salt thereof, wherein each R d is independently selected from a C 1-4 alkyl or hydrogen and each R D is independently selected from hydrogen or C 1-4 alkyl.

32. The compound of claim 31 , or a pharmaceutically acceptable salt thereof, wherein each R d is independently selected from hydrogen or methyl and each R D is independently selected from hydrogen, methyl, ethyl, propyl or isopropyl.

33. The compound of claim 32 , or a pharmaceutically acceptable salt thereof, wherein each R d and each R D is independently selected from hydrogen or methyl.

34. The compound of claim 24 , wherein o is 1, 2 or 3 and each J D is independently selected from methyl, fluoro, —N(R D ) 2 , —N(R d )C(O)R D , —N(R d )C(O)OR D , —SO 2 R D , —SO 2 N(R D ) 2 or —N(R d )SO 2 R D ; wherein each R d and each R D is independently selected from hydrogen or methyl.

35. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R C is —CN.

36. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R C is a C 1-6 alkyl.

37. The compound of claim 36 , or a pharmaceutically acceptable salt thereof, wherein R C is selected from methyl, ethyl, propyl, isopropyl or butyl.

38. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R C is a ring C.

39. The compound of claim 38 , or a pharmaceutically acceptable salt thereof, wherein ring C is a phenyl, a monocyclic 5 or 6-membered heteroaryl ring, a monocyclic 3 to 10-membered cycloaliphatic ring or a monocyclic 4 to 10-membered heterocycle; each of them optionally and independently substituted with up to 3 instances of J C .

40. The compound of claim 39 , or a pharmaceutically acceptable salt thereof, wherein ring C is a phenyl, a monocyclic 5 or 6-membered heteroaryl ring, a monocyclic 3 to 6-membered cycloaliphatic ring or a monocyclic 4 to 6-membered heterocycle; each of them optionally and independently substituted with up to 3 instances of J C .

41. The compound of claim 40 , or a pharmaceutically acceptable salt thereof, wherein ring C is a monocyclic 3 to 6-membered cycloaliphatic ring, optionally substituted with up to 2 instances of J C .

42. The compound of claim 41 , or a pharmaceutically acceptable salt thereof, wherein ring C is cyclopropyl.

43. The compound of claim 41 , or a pharmaceutically acceptable salt thereof, wherein ring C is cyclobutyl.

44. The compound of claim 41 , or a pharmaceutically acceptable salt thereof, wherein ring C is cyclopentyl.

45. The compound of claim 41 , or a pharmaceutically acceptable salt thereof, wherein ring C is cyclohexyl.

46. The compound of claim 41 , or a pharmaceutically acceptable salt thereof, wherein ring C is a 4-membered cycloaliphatic ring substituted by 1 to 3 instances of J C , a 5-membered cycloaliphatic ring substituted by 1 to 3 instances of J C or a 6-membered cycloaliphatic ring substituted by 1 to 3 instances of J C , and wherein each J C is independently selected from halogen or a C 1-6 aliphatic.

47. The compound of claim 40 , or a pharmaceutically acceptable salt thereof, wherein ring C is phenyl, optionally and independently substituted by up to 3 instances of J C .

48. The compound of claim 47 , or a pharmaceutically acceptable salt thereof, wherein ring C is phenyl and it is unsubstituted.

49. The compound of claim 47 , or a pharmaceutically acceptable salt thereof, wherein ring C is substituted by 1 to 3 instances of J C and wherein each J C is independently selected from halogen, a C 1-6 aliphatic, —NH 2 , —CN or —O(C 1-6 aliphatic).

50. The compound of claim 49 , or a pharmaceutically acceptable salt thereof, wherein each J C is independently selected from halogen, a C 1-4 alkyl, —O(C 1-4 alkyl), —CN or —NH 2 .

51. The compound of claim 50 , or a pharmaceutically acceptable salt thereof, wherein ring C is phenyl substituted by 1 to 2 instances of J C .

52. The compound of either of claims 50 or 51 , or a pharmaceutically acceptable salt thereof, wherein each J C is independently selected from fluoro, methyl, —CN or —OCH 3 .

53. The compound of claim 40 , or a pharmaceutically acceptable salt thereof, wherein ring C is a 5 to 6-membered heteroaryl ring, optionally substituted by up to 3 instances of J C .

54. The compound of claim 40 , or a pharmaceutically acceptable salt thereof, wherein ring C is a 5 to 6-membered heteroaryl ring and it is unsubstituted.

55. The compound of either of claims 53 or 54 , or a pharmaceutically acceptable salt thereof, wherein said 5 to 6-membered heteroaryl ring is selected from thienyl, thiazolyl, oxadiazolyl, oxazolyl, isooxazolyl, tetrazolyl, pyrrolyl, triazolyl, furanyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl.

56. The compound of claim 55 , or a pharmaceutically acceptable salt thereof, wherein said 5 to 6-membered heteroaryl ring is selected from furanyl, thienyl, thiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrimidinyl or pyrazin-3-yl.

57. The compound of claim 56 , or a pharmaceutically acceptable salt thereof, wherein said 5 to 6-membered heteroaryl ring is selected from thienyl, thiazolyl, 1,3,4-oxadiazolyl or pyridinyl.

58. The compound of claim 56 , or a pharmaceutically acceptable salt thereof, wherein the 5 to 6-membered heteroaryl ring is selected from furan-2-yl, furan-3-yl, thien-3-yl, thien-2-yl, thiazol-2-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl or pyrimidin-4-yl; and is optionally substituted with up to 2 instances of J C .

59. The compound of claim 53 , or a pharmaceutically acceptable salt thereof, wherein each J C is independently selected from halogen, a C 1-6 aliphatic, —CN, —NH 2 or —O(C 1-6 aliphatic).

60. The compound of claim 53 , or a pharmaceutically acceptable salt thereof, wherein ring C is thienyl or pyridinyl substituted by 1 to 3 instances of J C and each J C is independently selected from a halogen, a C 1-6 aliphatic, —NH 2 or —O(C 1-6 aliphatic).

61. The compound of claim 60 , or a pharmaceutically acceptable salt thereof, wherein each J C is independently selected from a C 1-6 aliphatic.

62. The compound of claim 61 , or a pharmaceutically acceptable salt thereof, wherein each J C is independently selected from methyl, ethyl, propyl or isopropyl.

63. The compound of claim 60 , or a pharmaceutically acceptable salt thereof, wherein each J C is independently selected from a halogen atom, methyl, —NH 2 or —OCH 3 .

64. The compound of claim 38 , or a pharmaceutically acceptable salt thereof, wherein ring C is a bicyclic 7 to 10-membered heteroaryl ring.

65. The compound of claim 64 , or a pharmaceutically acceptable salt thereof, wherein ring C is benzofuran-2-yl, furo[3,2-b]pyridinyl, furo[2,3-b]pyridinyl, benzothienyl or indolyl.

66. The compound of claim 65 , or a pharmaceutically acceptable salt thereof, wherein ring C is benzofuran-2-yl, furo[3,2-b]pyridinyl or benzothienyl.

67. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein J D is —N(R d )C(O)OR D or —N(R D ) 2 , or two J D groups attached to two vicinal ring D atoms, taken together with said two vicinal ring D atoms, form a 5-membered heterocycle containing from 1 to 3 heteroatoms independently selected from N, O or S resulting in a fused ring D wherein said 5-membered heterocycle is optionally and independently substituted by up to 3 instances of halogen, —OH, —NH 2 , —NH(C 1-4 alkyl), —N(C 1-4 alkyl) 2 , —CN, C 1-4 alkyl, C 1-4 haloalkyl, —O(C 1-4 alkyl), —O(C 1-4 haloalkyl) or oxo having Formula II:

68. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, having Formula III or Formula IV:

69. The compound of claim 68 , or a pharmaceutically acceptable salt thereof, having one of Formulae VA, VC, VD and VF, wherein the symbol of the letter C surrounded by a circle represents ring C:

70. The compound of claim 68 , or a pharmaceutically acceptable salt thereof, wherein R C is oxazolyl optionally and independently substituted by up to 3 instances of J C .

71. The compound of claim 70 , wherein J D is selected from —N(R d )C(O)OR D or —N(R D ) 2 .

72. The compound of claim 71 , wherein J D is —N(R D ) 2 .

73. The compound of one of claims 70 , 71 or 72 , or a pharmaceutically acceptable salt thereof, having Formula IV, wherein R C is oxazolyl optionally and independently substituted by up to 3 instances of J C .

74. The compound of claim 1 , selected from Table IA, IB, IC or ID, or a pharmaceutically acceptable salt thereof.

75. The compound of claim 20 , or a pharmaceutically acceptable salt thereof, wherein X in ring D is C-J D or C—H.

76. The compound of claim 20 , or a pharmaceutically acceptable salt thereof, wherein X in ring D is N.

77. The compound of either claims 75 or 76 , or a pharmaceutically acceptable salt thereof, wherein o is 0.

78. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

79. A method of treating a disease, health condition or disorder in a subject, comprising administering a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, to the subject in need of the treatment, wherein the disease, health condition or disorder is pulmonary hypertension, pulmonary arterial hypertension, and associated pulmonary vascular remodeling, pulmonary hypertonia, primary pulmonary hypertension, secondary pulmonary hypertension, familial pulmonary hypertension, sporadic pulmonary hypertension, pre-capillary pulmonary hypertension or idiopathic pulmonary hypertension.